A triple incretin receptor agonist (GLP-1/GIP/glucagon) currently in Phase 3 clinical trials. Retatrutide activates all three receptor pathways simultaneously, a mechanism not present in any currently approved therapeutic. Phase 2b data showed mean weight reductions exceeding 17% at 24 weeks.
Retatrutide has been extensively studied across multiple research domains. Below are the primary areas of published research.
Browse on PubMed →